Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
IMODIUM is an oral solution small-molecule antidiarrheal agent approved in 1984 by Johnson & Johnson. The drug treats acute and chronic diarrhea by reducing intestinal motility. It is a well-established, mature therapeutic used across consumer and prescription channels.
With competitive pressure at 30% and LOE approaching, commercial teams are likely rightsizing and transitioning to post-patent defense strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Combination Caplet With Loperamide Hydrochloride and Simethicone, and Imodium Express Tablets-lyophilizate Coadministered With Espumisan Capsule in Healthy Volunteers
IMODIUM offers limited new career opportunities given its mature, LOE-approaching status and zero linked job openings. Working on this product provides stability and OTC/Rx hybrid experience but limited upside growth potential.
Worked on IMODIUM at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.